GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » AngioDynamics Inc (NAS:ANGO) » Definitions » Cyclically Adjusted Revenue per Share

ANGO (AngioDynamics) Cyclically Adjusted Revenue per Share : $9.34 (As of Feb. 2025)


View and export this data going back to 2004. Start your Free Trial

What is AngioDynamics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AngioDynamics's adjusted revenue per share for the three months ended in Feb. 2025 was $1.763. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $9.34 for the trailing ten years ended in Feb. 2025.

During the past 12 months, AngioDynamics's average Cyclically Adjusted Revenue Growth Rate was -3.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 0.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 1.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 1.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AngioDynamics was 5.20% per year. The lowest was -0.70% per year. And the median was 1.40% per year.

As of today (2025-05-14), AngioDynamics's current stock price is $9.29. AngioDynamics's Cyclically Adjusted Revenue per Share for the quarter that ended in Feb. 2025 was $9.34. AngioDynamics's Cyclically Adjusted PS Ratio of today is 0.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AngioDynamics was 3.26. The lowest was 0.55. And the median was 1.69.


AngioDynamics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for AngioDynamics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AngioDynamics Cyclically Adjusted Revenue per Share Chart

AngioDynamics Annual Data
Trend May15 May16 May17 May18 May19 May20 May21 May22 May23 May24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.21 9.40 9.93 9.91 9.66

AngioDynamics Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.72 9.66 9.53 9.39 9.34

Competitive Comparison of AngioDynamics's Cyclically Adjusted Revenue per Share

For the Medical Instruments & Supplies subindustry, AngioDynamics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AngioDynamics's Cyclically Adjusted PS Ratio falls into.


;
;

AngioDynamics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AngioDynamics's adjusted Revenue per Share data for the three months ended in Feb. 2025 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=1.763/134.6241*134.6241
=1.763

Current CPI (Feb. 2025) = 134.6241.

AngioDynamics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201505 2.511 100.333 3.369
201508 2.329 100.548 3.118
201511 2.471 100.135 3.322
201602 2.403 100.040 3.234
201605 2.567 101.355 3.410
201608 2.401 101.617 3.181
201611 2.397 101.829 3.169
201702 2.306 102.779 3.021
201705 0.192 103.256 0.250
201708 2.313 103.587 3.006
201711 2.319 104.072 3.000
201802 2.239 105.052 2.869
201805 0.153 106.148 0.194
201808 1.713 106.383 2.168
201811 1.866 106.338 2.362
201902 1.746 106.649 2.204
201905 1.893 108.048 2.359
201908 1.748 108.245 2.174
201911 1.843 108.519 2.286
202002 1.836 109.139 2.265
202005 1.532 108.175 1.907
202008 1.840 109.662 2.259
202011 1.899 109.793 2.328
202102 1.856 110.968 2.252
202105 1.994 113.576 2.364
202108 1.987 115.421 2.318
202111 2.004 117.269 2.301
202202 1.892 119.703 2.128
202205 2.222 123.323 2.426
202208 2.075 124.958 2.236
202211 2.163 125.607 2.318
202302 2.043 126.928 2.167
202305 2.299 128.314 2.412
202308 1.969 129.538 2.046
202311 1.966 129.548 2.043
202402 1.869 130.930 1.922
202405 1.756 132.509 1.784
202408 1.660 132.816 1.683
202411 1.780 133.110 1.800
202502 1.763 134.624 1.763

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


AngioDynamics  (NAS:ANGO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AngioDynamics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.29/9.34
=0.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AngioDynamics was 3.26. The lowest was 0.55. And the median was 1.69.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AngioDynamics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of AngioDynamics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AngioDynamics Business Description

Traded in Other Exchanges
Address
14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
Executives
Warren Jr Nighan officer: SVP Quality and Regulatory ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Stephen A Trowbridge officer: SVP and General Counsel 14 PLAZA DRIVE, LATHAM NY 120110
James C Clemmer director, officer: President and CEO COVIDIEN PLC, 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Lorinda Burgess director 22 WEST FRONTAG ROAD, NORTHBROOK IL 60093
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Michael E Tarnoff director C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Scott Centea officer: SVP/GM, VIT C/O ANGIODYNAMICS, INC., 14 PLAZA DRIVE, LATHAM NY 12110
Dave Helsel officer: SVP Global Operations and R&D 400 WOOD ROAD, BRAINTREE MA 02184
Laura Piccinini officer: SVP International C/O ANGIODYNAMICS INC., 14 PLAZA DRIVE, LATHAM NY 12110
Wesley Johnson director
Chad Thomas Campbell officer: SVP/GM, Vascular Access 140 POKANOKET PATH, WRENTHAM MA 02093
Richard C Rosenzweig officer: SVP and General Counsel C/O DENTSPLY SIRONA INC., 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Kevin J Gould director 247 WASHINGTON STREET, DUXBURY MA 02332
Brent J. Boucher officer: SVP and GM of Oncology 14 PLAZA DRIVE, LATHAM NY 12110
Michael Greiner officer: EVP and CFO C/O VISTAPRINT, 95 HAYDEN AVENUE, LEXINGTON MA 02421